| 000 | 01670 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515095822.0 | ||
| 264 | 0 | _c20080530 | |
| 008 | 200805s 0 0 eng d | ||
| 022 | _a0393-2990 | ||
| 024 | 7 |
_a10.1007/s10654-007-9212-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWinkelmayer, Wolfgang C | |
| 245 | 0 | 0 |
_aUse of recommended medications after myocardial infarction in Austria. _h[electronic resource] |
| 260 |
_bEuropean journal of epidemiology _c2008 |
||
| 300 |
_a153-62 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenergic beta-Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xtherapeutic use |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aAustria _xepidemiology |
| 650 | 0 | 4 | _aDrug Utilization Review |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyocardial Infarction _xdrug therapy |
| 650 | 0 | 4 | _aNational Health Programs |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 |
_aPractice Patterns, Physicians' _xstatistics & numerical data |
| 650 | 0 | 4 | _aSecondary Prevention |
| 700 | 1 | _aBucsics, Anna E | |
| 700 | 1 | _aSchautzer, Alexandra | |
| 700 | 1 | _aWieninger, Peter | |
| 700 | 1 | _aPogantsch, Michaela | |
| 773 | 0 |
_tEuropean journal of epidemiology _gvol. 23 _gno. 2 _gp. 153-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10654-007-9212-4 _zAvailable from publisher's website |
| 999 |
_c17578507 _d17578507 |
||